The cost effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data

被引：0
|
作者：
Kobelt, G.
Andlin-Sobocki, P.
Collantes-Estevez, E.
Gratacos-Masmitja, J.
Pocovi, A.
Mulero-Mendoza, J.
机构：
[1] European Hlth Econ, Stockholm, Sweden
[2] Stockholm Hlth Econ, Stockholm, Sweden
[3] Hosp Reina Sofia, Cordoba, Spain
[4] Hosp Sabadell, Barcelona, Spain
[5] Schering Plough Corp, Madrid, Spain
[6] Clin Puerta Hierro, Madrid, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：282 / 283
页数：2
相关论文
共 50 条
  • [1] The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data
    Kobelt, G.
    Sobocki, P.
    Mulero, J.
    Gratacos, J.
    Collantes-Estevez, E.
    Braun, J.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 (01) : 62 - 71
  • [2] Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials
    Kobelt, Gisela
    Sobocki, Patrik
    Sieper, Joachim
    Braun, Juergen
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2007, 23 (03) : 368 - 375
  • [3] Low-dose infliximab for ankylosing spondylitis in clinical practice -? More cost effective
    Jois, RN
    Leeder, J
    Gibb, A
    Gaffney, K
    Merry, P
    Scott, DGI
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 320 - +
  • [4] Low-dose infliximab for ankylosing spondylitis in clinical practice -: ? More cost effective
    Jois, RN
    Leeder, J
    Gibb, A
    Gaffney, K
    Merry, P
    Scott, DGI
    RHEUMATOLOGY, 2005, 44 : I117 - I117
  • [5] Clinical predictors of response to treatment with infliximab in ankylosing spondylitis (AS).
    Stone, M
    Salonen, D
    Payne, U
    Lax, M
    Lapp, V
    Inman, R
    ARTHRITIS AND RHEUMATISM, 2000, 43 (12): : 2857 - 2857
  • [6] Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice
    Escudero-Vilaplana, Vicente
    Ramirez-Herraiz, Esther
    Alanon-Plaza, Estefania
    Trovato-Lopez, Nicolas
    Garcia-Vicuna, Rosario
    Carreno-Perez, Luis
    Morell-Baladron, Alberto
    Sanjurjo-Saez, Maria
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (05) : 808 - 814
  • [7] Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice
    Vicente Escudero-Vilaplana
    Esther Ramírez-Herráiz
    Estefanía Alañón-Plaza
    Nicolás Trovato-López
    Rosario García-Vicuña
    Luis Carreño-Pérez
    Alberto Morell-Baladrón
    María Sanjurjo-Sáez
    International Journal of Clinical Pharmacy, 2015, 37 : 808 - 814
  • [8] The cost-effectiveness of infliximab (Remicade®) in the treatment of ankylosing spondylitis in Canada
    Kobelt, G
    Andlin-Sobocki, P
    Maksymowych, WP
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (04) : 732 - 740
  • [9] The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade®)
    Kobelt, G
    Andlin-Sobocki, P
    Brophy, S
    Jönsson, L
    Calin, A
    Braun, J
    RHEUMATOLOGY, 2004, 43 (09) : 1158 - 1166
  • [10] Cost-effectiveness of infliximab for ankylosing spondylitis (AS) in Canada
    Kobelt, G
    Andlin-Sobocki, P
    Maksymowych, W
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 406 - 406
12345